GBM Agile, study for newly diagnoses and recurrent glioblastomas

UVA Tracking #
Principal Investigator
David Schiff
Contact Phone
Official Trial Title
GBM AGILE Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent Glioblastoma (GBM)
Study Description

The Neuro-oncology team at UVA seeks adults ages > 18 with a newly diagnosed or recurrent glioblastoma (GBM) for a research study. The purpose of the study is to determine if different experimental treatments improve the overall survival of patients with glioblastoma.

You may be eligible for this study if: you have a newly diagnosed glioblastoma (GBM) and have not received any treatment other than surgery. Or if you have a glioblastoma (GBM) that has returned despite receiving prior treatment.

Study involves randomization to either standard of care or an experimental medication. The number of visits, study procedures and amount of time in the study is determined by the randomized treatment group.

Participant’s insurance company will be billed for medication, tests and procedures.



No Compensation